Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer

Apomab, a fully human agonistic DR5 monoclonal antibody, triggers apoptosis through activation of the extrinsic apoptotic signaling pathway. In this study, we assessed the cytotoxic effect of Apomab in vitro and evaluated its antitumor activity in murine models of breast cancer development and progr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mol Cancer Ther
Autors principals: Zinonos, Irene, Labrinidis, Agatha, Lee, Michelle, Liapis, Vasilios, Hay, Shelley, Ponomarev, Vladimir, Diamond, Peter, Zannettino, Andrew C.W., Findlay, David M., Evdokiou, Andreas
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5568046/
https://ncbi.nlm.nih.gov/pubmed/19808976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-09-0745
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars